Company news
Savara, Inc. (NASDAQ:SVRA) news
Every Savara, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Au...
August 24, 2026
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protecti...
July 30, 2026
Savara Announces Chief Financial and Administrative Officer Transition
June 8, 2026
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoim...
May 20, 2026
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgram...
May 19, 2026
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) i...
May 18, 2026
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
May 11, 2026
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgr...
April 15, 2026
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
April 14, 2026
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation ...
April 7, 2026
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pul...
March 30, 2026
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 13, 2026
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
March 6, 2026
Savara Announces Participation in 2026 Citizens Life Sciences Conference
March 4, 2026
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmo...
February 20, 2026
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Admi...
January 27, 2026
Savara Announces New Employment Inducement Grant
January 16, 2026
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
January 8, 2026
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential ...
December 22, 2025
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
December 11, 2025
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebuliz...
December 2, 2025
Savara Announces Participation in Upcoming Investor Healthcare Conferences
November 20, 2025
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross P...
October 31, 2025
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar P...
October 29, 2025
Savara Announces Proposed Public Offering
October 29, 2025
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
October 29, 2025
Savara Announces Chief Medical Officer (CMO) Transition
October 17, 2025
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramost...
October 2, 2025
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Aut...
September 29, 2025
Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Pr...
September 2, 2025
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary A...
August 20, 2025
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune...
August 18, 2025
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update
August 13, 2025
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA)...
May 27, 2025
Savara Announces Participation in Jefferies Global Healthcare Conference
May 22, 2025
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimm...
May 18, 2025
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
May 13, 2025
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
May 12, 2025
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
May 1, 2025
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
May 1, 2025
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With...
April 7, 2025
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
March 27, 2025
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a...
March 26, 2025
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
March 26, 2025
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune...
March 17, 2025
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
March 6, 2025
Savara Announces Participation in the Leerink Global Healthcare Conference
March 3, 2025